Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre on February 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.48 USD | -0.09% | -0.14% | +123.52% |
EPS Revisions
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Fusion Pharmaceuticals Inc. agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.